Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis
| Autor: | P. Mark Bartold, Melissa Cantley, David R. Haynes, Victor Marino, David P. Fairlie, Praveer Gupta |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Lipopolysaccharides
Chemokine animal structures Pyridines medicine.drug_class medicine.medical_treatment Osteoclasts Arthritis Histone Deacetylase 1 Inflammation In Vitro Techniques Hydroxamic Acids Monocytes Mice Rheumatology Osteoclast medicine Animals Humans Pharmacology (medical) Bone Resorption Cells Cultured Mice Inbred BALB C biology Tumor Necrosis Factor-alpha business.industry Histone deacetylase inhibitor medicine.disease Arthritis Experimental HDAC1 Histone Deacetylase Inhibitors Disease Models Animal Cytokine medicine.anatomical_structure Benzamides biology.protein Cancer research Cytokines Female Histone deacetylase Chemokines medicine.symptom business |
| Zdroj: | Rheumatology. 54:1713-1723 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/kev022 |
| Popis: | Histone deacetylase 1 (HDAC1) is highly expressed in the synovium of RA patients. Thus we aimed to investigate a novel HDAC inhibitor (HDACi), NW-21, designed to target HDAC1. The effect of NW-21 on osteoclast formation and activity, cytokine and chemokine expression in vitro and arthritis in mice was assessed.The effects on human osteoclast formation and activity derived from human blood monocytes stimulated with receptor activator of nuclear factor κB ligand (RANKL) and M-CSF were assessed. The anti-inflammatory activity of NW-21 was assessed using human monocytes stimulated with either TNF-α or lipopolysaccharide for 24 h. mRNA expression of monocyte chemotactic protein 1 (MCP-1), TNF-α, macrophage inflammatory protein 1α (MIP-1α), IL-1 and RANTES (regulated on activation, normal T cell expressed and secreted) was assessed. The effect of NW-21 in the collagen antibody-induced arthritis model was assessed following daily oral administration at 5 mg/kg/day. The HDAC1 inhibitors NW-21 and MS-275 were compared with a broad-acting HDACi, 1179.4b. Effects on inflammation and bone were assessed using paw inflammation scoring, histology and live animal micro-CT.NW-21 suppressed osteoclast formation and activity as well as significantly reducing mRNA expression of MCP-1 and MIP-1α in monocytes stimulated by lipopolysaccharide or TNF-α (P0.05) in vitro. Only inhibitors that targeted HDAC1 (NW-21 and MS-275) reduced inflammation and bone loss in the arthritis model.The results indicate that inhibitors targeting HDAC1, such as NW-21 and MS-275, may be useful for treating RA, as such drugs can simultaneously target both inflammation and bone resorption. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|